<DOC>
	<DOCNO>NCT00702585</DOCNO>
	<brief_summary>The objective trial investigate feasibility optimal dose single administration Org 36286 induce monofollicular ovulation woman WHO Group II anovulatory infertility ass safety ( include absence antibody formation ) Org 36286 .</brief_summary>
	<brief_title>Study Investigate Optimal Dose Org 36286 Induce Monofollicular Ovulation Women With WHO Group II Anovulatory Infertility ( P07016 )</brief_title>
	<detailed_description>This phase II , randomize , double-blind , placebo control , comparative trial investigate optimal dose single administration Org 36286 induce monofollicular ovulation woman WHO Group II anovulatory infertility . Treatment injection give Day 1-3 onset spontaneous progestagen induce withdrawal bleeding . After injection , ultrasound monitoring sample serum hormone do treatment Days 3 , 5 , daily Day 7 21 urinary luteinizing hormone ( LH ) peak detect . From treatment Day 7 urinary LH response assess detect preovulatory LH peak . In case hyperstimulation , production endogenous gonadotropin could suppress give daily injection GnRH antagonist . Post-treatment assessment do third week urinary LH peak . If LH peak detect , posttreatment assessment perform four five week Org 36286 placebo injection .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<criteria>Wish conceive ; Oligomenorrhea ( cycle length &gt; =41 day ) amenorrhea ( menstrual cycle &gt; 6 month ) ; Body Mass Index ( BMI ) &gt; =18 &lt; =32 kg/m^2 ; Serum FSH level within normal limit ( 110 IU/L ) ; Normal serum prolactin thyroid stimulate hormone ( TSH ) level ; Progestagen induce withdrawal bleed spontaneous menstrual bleeding ; Tumours ovary , breast , uterus , pituitary hypothalamus ; Pregnancy lactation ; Undiagnosed vaginal bleeding ; Ovarian cyst enlarge ovary relate polycystic ovarian disease ( PCOD ) ; Any ovarian and/or abdominal abnormality interfere ultrasound examination ; Malformations sexual organ incompatible pregnancy ; Clomiphene resistance document anovulation ( treated 150 mg clomiphene five day ovulation ) ; Treatment metformin , gonadotropin , GnRH analog within 90 day prior start Org 36286 treatment ; Treatment clomiphene citrate within 42 day prior start Org 36286 treatment ; Alcohol drug abuse within 12 month precede signing informed consent ; Any clinically relevant abnormal laboratory value ; Hypersensitivity substances Org 36286 ; Hypersensitivity OrgalutranÂ® component ; Use investigational drug 90 day screen previous participation trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Ovulation Induction</keyword>
	<keyword>Pharmacological effect drug</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormone substitute Hormone Antagonists</keyword>
	<keyword>Pharmacological Actions</keyword>
	<keyword>Randomized</keyword>
	<keyword>Multi-center</keyword>
	<keyword>Multi-national</keyword>
</DOC>